2022
In vivo correction of cystic fibrosis mediated by PNA nanoparticles
Piotrowski-Daspit AS, Barone C, Lin CY, Deng Y, Wu D, Binns TC, Xu E, Ricciardi AS, Putman R, Garrison A, Nguyen R, Gupta A, Fan R, Glazer PM, Saltzman WM, Egan ME. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. Science Advances 2022, 8: eabo0522. PMID: 36197984, PMCID: PMC9534507, DOI: 10.1126/sciadv.abo0522.Peer-Reviewed Original ResearchCystic fibrosisF508del miceIntravenous deliveryPrimary nasal epithelial cellsMultiple organ dysfunctionNasal epithelial cellsUssing chamber assaysOrgan dysfunctionF508del cystic fibrosisVivo treatmentGI tissuesCF transmembrane conductance regulator (CFTR) geneChamber assaySystemic deliveryEpithelial cellsCF-causing mutationsFibrosisCFTR functionMiceTransmembrane conductance regulator geneTarget effectsAir-liquid interfaceDeliveryPartial gainViable option
2016
Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease
Spirli C, Mariotti V, Villani A, Fabris L, Fiorotto R, Strazzabosco M. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease. Journal Of Hepatology 2016, 66: 571-580. PMID: 27826057, PMCID: PMC5316496, DOI: 10.1016/j.jhep.2016.10.032.Peer-Reviewed Original ResearchMeSH KeywordsAdenylyl Cyclase InhibitorsAdenylyl CyclasesAnimalsCalciumCell ProliferationCyclic AMPCystsDisease Models, AnimalHomeostasisHumansLiver DiseasesMAP Kinase Signaling SystemMiceMice, KnockoutPolycystic Kidney, Autosomal DominantRNA InterferenceSignal TransductionStromal Interaction Molecule 1TRPP Cation ChannelsVascular Endothelial Growth Factor AConceptsProgressive cyst growthPolycystic liver diseaseNovel therapeutic targetLiver diseaseKO miceCyst growthTherapeutic targetBiliary organoidsDouble conditional knockout miceCAMP productionAutosomal dominant polycystic kidney diseaseVascular endothelial growth factorCell proliferationDominant polycystic kidney diseaseEndothelial growth factorConditional knockout micePolycystic kidney diseaseLiver transplantationLevels of cAMPStore-operated CaCystic areasKidney diseaseCyst sizeVivo treatmentKnockout mice
2015
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells. Oncotarget 2015, 6: 37410-37425. PMID: 26485762, PMCID: PMC4741938, DOI: 10.18632/oncotarget.6138.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisApoptosis Regulatory ProteinsAzepinesAzocinesBenzhydryl CompoundsCamptothecinCell Line, TumorCell ProliferationDocetaxelDose-Response Relationship, DrugDrug SynergismFemaleHumansIrinotecanLung NeoplasmsMice, Inbred BALB CMice, NudeNF-kappa BPaclitaxelSignal TransductionTaxoidsTime FactorsTopoisomerase InhibitorsTriazolesTumor BurdenXenograft Model Antitumor AssaysConceptsLung adenocarcinoma cellsDebio 1143Adenocarcinoma cellsOngoing clinical trialsNon-canonical NF-κB signalingTopoisomerase inhibitorsLung adenocarcinoma xenograftsNF-κB signalingBromodomain inhibitor JQ1Clinical trialsConventional chemotherapyTumor volumeVivo treatmentAdenocarcinoma xenograftsAnti-apoptotic proteinsSingle agentCaspase-8 expressionVivo growthInhibitor JQ1Tumor cellsPro-apoptotic protein SmacJQ1Cell linesInhibitorsTaxanes
2013
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer
Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer. International Journal Of Cancer 2013, 134: 596-605. PMID: 23873170, PMCID: PMC3830586, DOI: 10.1002/ijc.28390.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBase SequenceCell Cycle ProteinsCell Line, TumorColorectal NeoplasmsDeoxycytidineDNA MethylationDNA PrimersDocetaxelFemaleGemcitabineGene SilencingHumansMiceMicrosatellite InstabilityNeoplasm ProteinsPoly-ADP-Ribose Binding ProteinsPromoter Regions, GeneticReal-Time Polymerase Chain ReactionTaxoidsUbiquitin-Protein LigasesXenograft Model Antitumor AssaysConceptsTumor growth inhibitionColorectal cancerCombination therapyCHFR methylationCell linesAdditive tumor growth inhibitionBiomarker-selected patient populationsMicrosatellite instabilityGrowth inhibitionOngoing clinical trialsCRC cell linesCell line xenograftsMSI-H cell linesCRC patientsChemotherapy responsePatient populationPredictive markerClinical trialsDifferential sensitivityTherapeutic effectHuman xenograftsVivo treatmentMSI statusChemotherapy sensitivityGemcitabine
2012
Transient mGlu5R inhibition enhances the survival of granule cell precursors in the neonatal cerebellum
Kubera C, Hernandez AL, Heng V, Bordey A. Transient mGlu5R inhibition enhances the survival of granule cell precursors in the neonatal cerebellum. Neuroscience 2012, 219: 271-279. PMID: 22677205, PMCID: PMC3402690, DOI: 10.1016/j.neuroscience.2012.05.064.Peer-Reviewed Original ResearchConceptsExternal germinal layerGranule cell precursorsGranule cellsS-phase marker bromodeoxyuridineMetabotropic glutamate receptor 5Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stainingTransferase dUTP nick end labeling stainingCell precursorsDUTP nick end labeling stainingNick end labeling stainingGlutamate receptor 5Postnatal day 2Proliferative granule cell precursorsEnd labeling stainingCerebellar granule cellsAcute slicesAbundant neuronsBrdU injectionLabeling stainingVivo treatmentReceptor 5Day 2Vivo injectionSpecific receptorsClonal expansion
2010
Expansion of CD3+/CD4+/CD25+/Foxp3+ T cells in rapamycin-treated lupus patients (143.52)
Perl A, Lai Z, Telarico T, Bartos A, Miklossy G, Hanczko R, Francis L, Tily H, Ramos I, Garcia R, Phillips P, Jimah J, Doherty E. Expansion of CD3+/CD4+/CD25+/Foxp3+ T cells in rapamycin-treated lupus patients (143.52). The Journal Of Immunology 2010, 184: 143.52-143.52. DOI: 10.4049/jimmunol.184.supp.143.52.Peer-Reviewed Original ResearchSLE patientsT cellsLupus patientsSystemic lupus erythematosus patientsMitochondrial hyperpolarizationFemale SLE patientsFrequency of TregsPrevalence of Foxp3Lupus erythematosus patientsT cell activationSLEDAI scoreHealthy controlsVivo treatmentPatientsB cellsFemale controlsTherapeutic efficacyCell activationMammalian targetVivo expansionMTOR activityRapamycin treatmentPotential mechanismsTregsRapamycin
1987
B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes.
Antin JH, Ault KA, Rappeport JM, Smith BR. B lymphocyte reconstitution after human bone marrow transplantation. Leu-1 antigen defines a distinct population of B lymphocytes. Journal Of Clinical Investigation 1987, 80: 325-332. PMID: 3112184, PMCID: PMC442241, DOI: 10.1172/jci113076.Peer-Reviewed Original ResearchConceptsLeu-1B cellsMarrow transplantationHuman bone marrow transplantationEffect of GVHDHuman marrow transplantationBone marrow transplantationEx vivo treatmentInterleukin-2 receptorB lymphocyte reconstitutionSeparate B cell lineageNormal B cellsB-cell lineageAcute GVHDChronic graftHost diseaseLymphocyte reconstitutionDonor originVivo treatmentB lymphocytesMultivariate analysisStages of differentiationGVHDTransplantationMarrow
1984
Hepatic insulin resistance in non-insulin-dependent diabetes mellitus and the effects of a sulfonylurea in potentiating insulin action.
Amatruda J, Salhanick A, Chang C. Hepatic insulin resistance in non-insulin-dependent diabetes mellitus and the effects of a sulfonylurea in potentiating insulin action. Diabetes Care 1984, 7 Suppl 1: 47-53. PMID: 6376029.Peer-Reviewed Original ResearchConceptsLiver particulate fractionInsulin resistanceDiabetes mellitusInsulin actionHepatic insulin responsivenessPrimary culturesDependent diabetes mellitusRelease of mediatorsSerum glucose levelsStreptozotocin-diabetic animalsHepatic insulin resistanceEffect of insulinAbility of insulinDiabetic animalsDiabetic stateSerum glucoseInsulin treatmentGlucose levelsVivo treatmentControl animalsHepatic lipogenesisParticulate fractionInsulin responsivenessMellitusInsulin binding
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply